Apogee Companies

Apogee Therapeutics is a clinical-stage biotechnology company focused on developing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease (COPD), asthma, and other inflammatory and immunology (I&I) diseases. The company's pipeline is built on clinically validated targets, utilizing advanced antibody engineering to optimize half-life and dosing frequency, with the goal of providing best-in-class efficacy and less frequent administration. Its lead candidate, zumilokibart (APG777), is a subcutaneous monoclonal antibody targeting IL-13, currently in Phase 2 trials for atopic dermatitis. Apogee was founded as a spin-out from Paragon Therapeutics and is headquartered in Waltham, Massachusetts.